EDIT supply chain intelligence for Editas Medicine, Inc.: verified suppliers, customers, debt relationships, acquisitions, and ownership data.
Data compiled by Redley Lamar · ChainSifter Intelligence
Editas Medicine, Inc. (EDIT) is shown with relationship data already present in ChainSifter's database. Counts below come from stored supply-chain records and filing/source URLs where available; missing source URLs are not filled in or estimated.
| Ticker | Name | Confidence | Evidence |
|---|---|---|---|
| BROAD-INSTITUTE | BROAD-INSTITUTE | 92% | Editas Medicine is the exclusive licensee of Broad Institute’s Cas12a patent estate and Broad Institute and Harvard University’s Cas9 patent estates for human medicines. |
| HARVARD-UNIVERSITY | HARVARD-UNIVERSITY | 92% | Editas Medicine is the exclusive licensee of Broad Institute’s Cas12a patent estate and Broad Institute and Harvard University’s Cas9 patent estates for human medicines. |
| BMS | BMS | 90% | We have the right to terminate the BMS License Agreement on a program-by-program basis in the event that BMS fails to make any undisputed payment to us and has not cured such payment breach within th… |
| DRI-HEALTHCARE-ACQUISITIONS-LP | DRI-HEALTHCARE-ACQUISITIONS-LP | 85% | payments received under a purchase and sale agreement with DRI Healthcare Acquisitions LP |
| PRESIDENT-AND-FELLOWS-OF-HARVARD-COLLEGE | PRESIDENT-AND-FELLOWS-OF-HARVARD-COLLEGE | 80% | In October 2014, we entered into a license agreement with Broad and Harvard for specified patent rights. |
| THE-BROAD-INSTITUTE | THE-BROAD-INSTITUTE | 80% | In October 2014, we entered into a license agreement with Broad and Harvard for specified patent rights. |
| BEAM | Beam Therapeutics Inc. | 72% | Reciprocal relationship from BEAM graph: it of $1.7 billion. We expect to continue to incur significant expenses and increasing operating losses in connection with ongoing development activities rela… |
| CELG-RI | CELG-RI | 72% | ay regulatory approval of our product candidates. We cannot predict the likelihood, nature or extent of government regulation that may arise from future legislation or administrative action, either i… |
| CELG-RI | CELG-RI | 72% | Reciprocal relationship from CELG-RI graph: Reciprocal relationship from EDIT graph: ay regulatory approval of our product candidates. We cannot predict the likelihood, nature or extent of government… |
| IMTX | Immatics N.V. | 72% | Reciprocal relationship from IMTX graph: expired Service Options outstanding on December 31, Service Options exercisable on December 31, Weighted average remaining contract life (years) Service Optio… |
| INAB | IN8bio, Inc. | 72% | Reciprocal relationship from INAB graph: nt to the UABRF license agreement, see the section titled “Business—Intellectual Property.” Sales and Marketing Given our stage of development, we have not ye… |
| MGX | Metagenomi Therapeutics, Inc. | 72% | Reciprocal relationship from MGX graph: Reciprocal relationship from EDIT graph: Reciprocal relationship from MGX graph: Reciprocal relationship from EDIT graph: Reciprocal relationship from MGX grap… |
| PRME | Prime Medicine, Inc. | 72% | Reciprocal relationship from PRME graph: tic effect in such experiments or studies or they may have other characteristics that may make the product candidates impractical to manufacture, unmarketable… |
| SNYNF | Sanofi | 72% | Reciprocal relationship from SNYNF graph: Reciprocal relationship from EDIT graph: Reciprocal relationship from SNYNF graph: Reciprocal relationship from EDIT graph: ents with third-party manufacture… |
| SNYNF | Sanofi | 72% | ents with third-party manufacturers to obtain finished drug products that are appropriately packaged for sale; • successful development of our internal manufacturing processes and transfer to larger-… |
| VRTX | Vertex Pharmaceuticals Incorporated | 72% | Reciprocal relationship from VRTX graph: SPR JDCA, subject to CRISPR’s reserved right to conduct certain activities. We are reimbursed by CRISPR for its 40 % share of these research and development a… |
| Ticker | Name | Confidence | Evidence |
|---|---|---|---|
| BMS | BMS | 92% | The increase was attributable to recognition of the remaining deferred revenue upon the conclusion of a collaboration agreement with a strategic partner, as well as recognition of revenue related to … |
| STRATEGIC-PARTNER | STRATEGIC-PARTNER | 90% | The decrease is primarily attributable to the recognition of the remaining deferred revenue upon conclusion of a collaboration agreement with a strategic partner in 2025. |
| VERTEX-PHARMACEUTICALS-INC | VERTEX-PHARMACEUTICALS-INC | 90% | payments received under the Company’s license agreement with Vertex Pharmaceuticals, Inc |
| BEAM | Beam Therapeutics Inc. | 72% | Reciprocal relationship from BEAM graph: Reciprocal relationship from EDIT graph: Reciprocal relationship from BEAM graph: Reciprocal relationship from EDIT graph: Reciprocal relationship from BEAM g… |
| BMY | Bristol-Myers Squibb Company | 72% | dence due to the large volume of transactions and information obtained from multiple third-party vendors used by management in estimating the accrued expenses. Additionally, due to the timing and pat… |
| BMY | Bristol-Myers Squibb Company | 72% | Reciprocal relationship from BMY graph: Reciprocal relationship from EDIT graph: dence due to the large volume of transactions and information obtained from multiple third-party vendors used by manag… |
| BMYMP | Bristol-Myers Squibb Co | 72% | dence due to the large volume of transactions and information obtained from multiple third-party vendors used by management in estimating the accrued expenses. Additionally, due to the timing and pat… |
| BMYMP | Bristol-Myers Squibb Co | 72% | Reciprocal relationship from BMYMP graph: Reciprocal relationship from EDIT graph: Reciprocal relationship from BMYMP graph: Reciprocal relationship from EDIT graph: Reciprocal relationship from BMYM… |
| CELG-RI | CELG-RI | 72% | Reciprocal relationship from CELG-RI graph: Reciprocal relationship from EDIT graph: ay regulatory approval of our product candidates. We cannot predict the likelihood, nature or extent of government… |
| CELG-RI | CELG-RI | 72% | ay regulatory approval of our product candidates. We cannot predict the likelihood, nature or extent of government regulation that may arise from future legislation or administrative action, either i… |
| INAB | IN8bio, Inc. | 72% | Reciprocal relationship from INAB graph: nt to the UABRF license agreement, see the section titled “Business—Intellectual Property.” Sales and Marketing Given our stage of development, we have not ye… |
| MGX | Metagenomi Therapeutics, Inc. | 72% | Reciprocal relationship from MGX graph: amples of any lot of any approved product together with the protocols showing the results of applicable tests at any time. Under some circumstances, the FDA, t… |
| PRME | Prime Medicine, Inc. | 72% | Reciprocal relationship from PRME graph: tic effect in such experiments or studies or they may have other characteristics that may make the product candidates impractical to manufacture, unmarketable… |
| SNYNF | Sanofi | 72% | Reciprocal relationship from SNYNF graph: Reciprocal relationship from EDIT graph: ents with third-party manufacturers to obtain finished drug products that are appropriately packaged for sale; • suc… |
| SNYNF | Sanofi | 72% | ents with third-party manufacturers to obtain finished drug products that are appropriately packaged for sale; • successful development of our internal manufacturing processes and transfer to larger-… |
| ALLERGAN-PHARMACEUTICALS-INTERNATIONAL-LIMITED | ALLERGAN-PHARMACEUTICALS-INTERNATIONAL-LIMITED | 62% | dence due to the large volume of transactions and information obtained from multiple third-party vendors used by management in estimating the accrued expenses. Additionally, due to the timing and pat… |
| COMPANY-LLC | COMPANY-LLC | 62% | our consolidated financial statements appearing elsewhere in this Annual Report on Form 10-K, we believe the following accounting policies used in the preparation of our consolidated financial statem… |
| JUNO-THERAPEUTICS-INC | JUNO-THERAPEUTICS-INC | 62% | dence due to the large volume of transactions and information obtained from multiple third-party vendors used by management in estimating the accrued expenses. Additionally, due to the timing and pat… |
| Instrument | Description | Confidence | Evidence |
|---|---|---|---|
| EDIT-DEBT | Debt stack $55.7M | 90% | Market cache reports total debt of $55.7M. |
| Holder | Name | Confidence | Evidence |
|---|---|---|---|
| EDIT-OWNER-BLACKROCK-INC | BlackRock, Inc. | 90% | 13F overlay lists BlackRock, Inc. as top holder; 209 tracked holders. |
| Ticker | Name | Chain Index | Hops | Relationship Types |
|---|---|---|---|---|
| DBVTF | DBV TECHNOLOGIES | 100.00 | 2 | |
| CALC | CalciMedica, Inc. | 100.00 | 2 | |
| ALXO | ALX Oncology Holdings Inc. | 100.00 | 2 | |
| CHRS | Coherus Oncology, Inc. | 100.00 | 2 | |
| ANL | Adlai Nortye Ltd. | 100.00 | 2 | |
| ATOS | Atossa Therapeutics, Inc. | 100.00 | 2 | |
| EMMA | Emmaus Life Sciences, Inc. | 100.00 | 2 | |
| CYTOF | Altamira Therapeutics Ltd. | 100.00 | 2 | |
| BLRX | BioLineRx Ltd. | 100.00 | 2 | |
| BIOA | BioAge Labs, Inc. | 100.00 | 2 | |
| CYTK | Cytokinetics, Incorporated | 100.00 | 2 | |
| BEAM | Beam Therapeutics Inc. | 100.00 | 1 | ['customer', 'supplier'] |
| CBIO | Crescent Biopharma, Inc. | 100.00 | 2 | |
| CRBU | Caribou Biosciences, Inc. | 100.00 | 2 | |
| CCEP | Coca-Cola Europacific Partners PLC | 100.00 | 2 | |
| DSGN | Design Therapeutics, Inc. | 100.00 | 2 | |
| DTIL | Precision BioSciences, Inc. | 100.00 | 2 | |
| AZN | AstraZeneca PLC | 100.00 | 2 | |
| ANRO | Alto Neuroscience, Inc. | 100.00 | 2 | |
| CTMX | CytomX Therapeutics, Inc. | 100.00 | 2 |